Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach
In a new cost-analysis study, researchers recommend widespread testing of...
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations
Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide
Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet
Canada Research Chairs Program announces new and renewed chairs
Congratulations to five RI-MUHC researchers in the spring 2020 round!
Recipient of the 2020-2021 Dr. Margaret Becklake Fellowship: Mikashmi Kohli
A postdoctoral fellow from the RI-MUHC is recognized for international work on TB diagnostics
Three COVID-19 projects at the RI-MUHC to receive CIHR funding
A $109M fund aims to mitigate impact of the pandemic on care delivery in Canada and beyond, as well as contribute to better understanding of the disease
Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper
A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis
Why do some non-smokers get COPD while many heavy smokers don’t?
A new study highlights a strong risk factor for COPD related to lung development
Results of MI4 Emergency COVID-19 Research Funding (Round 2)
RI-MUHC researchers awarded MUHC Foundation funding for a second round of projects with potential impact in a short timeframe
We Care About Rare!
Researchers, advocates and patients gather on Rare Disease Research Day at the RI-MUHC